Institute of Oncology, HaEmek Medical Center, Afula, Israel.
Drug Discov Today. 2013 Feb;18(3-4):193-201. doi: 10.1016/j.drudis.2012.07.015. Epub 2012 Aug 4.
Low-dose metronomic (LDM) chemotherapy represents an emerging concept in the treatment of cancer. Directed against tumor cells and other types of cells, such as endothelial and immune cells, this treatment regimen alters the tumor microenvironment and suppresses innate features which support tumor growth. Ongoing Phase III clinical studies explore various applications of LDM chemotherapy, mostly combined with other anticancer agents, to act as complementary treatments to conventional maximum tolerated dose (MTD) chemotherapy. In this article we summarize preclinical and clinical experience with LDM chemotherapy, emphasizing the potential contribution of this new treatment modality to future paradigms in the systemic treatment of patients with cancer.
低剂量节拍化疗是癌症治疗中的一个新兴概念。这种治疗方案针对肿瘤细胞和其他类型的细胞，如内皮细胞和免疫细胞，改变肿瘤微环境并抑制支持肿瘤生长的固有特征。正在进行的 III 期临床试验探索了低剂量节拍化疗的各种应用，主要是与其他抗癌药物联合应用，作为常规最大耐受剂量（MTD）化疗的辅助治疗。本文总结了低剂量节拍化疗的临床前和临床经验，强调了这种新治疗模式对癌症患者系统治疗未来模式的潜在贡献。
